Walleye Capital
DNA icon

Walleye Capital’s Ginkgo Bioworks DNA Stock Holding History

Walleye Capital’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.6K Buy
+4,300
New +$36K ﹤0.01% 4230
2026
Q1 		– Sell
-33,400
Closed -$278K – 4520
2025
Q4 		$278K Buy
33,400
+31,800
+1,988% +$342K ﹤0.01% 3363
2025
Q3 		$23.3K Buy
+1,600
New +$19.1K ﹤0.01% 4186
2025
Q1 		– Sell
-7,300
Closed -$71.7K – 4417
2024
Q4 		$71.7K Sell
7,300
-10,100
-58% -$86.6K ﹤0.01% 4253
2024
Q3 		$142K Buy
+17,400
New +$174K ﹤0.01% 4217
2022
Q2 		– Sell
-500
Closed -$81K – 2452
2022
Q1 		$81K Buy
+500
New +$97.3K ﹤0.01% 1784

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Walleye Capital's DNA Position: Q2 2026 in Review

Walleye Capital opened a new position in Ginkgo Bioworks (DNA) in Q2 2026: 19,066 shares worth $189K. The stake represents ﹤0.01% of the portfolio and ranks #3540 among its holdings. This is a return to the name: Walleye Capital previously reported a position in DNA as recently as Q4 2025.

Walleye Capital first reported a position in DNA in Q3 2024 and has held it in 4 quarters since. The position peaked at $2.61M in Q4 2024. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Walleye Capital held 19,066 shares of Ginkgo Bioworks worth $189K as of Q2 2026.
  • Ginkgo Bioworks was a new Walleye Capital position in Q2 2026.
  • Ginkgo Bioworks made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3540 holding.
  • Walleye Capital first reported a position in Ginkgo Bioworks in Q3 2024 and has held it in 4 quarters since.
  • Walleye Capital's Ginkgo Bioworks position peaked at $2.61M in Q4 2024.
  • 183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.